Literature DB >> 11159597

MMR vaccine: the continuing saga.

D Elliman, H Bedford.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11159597      PMCID： PMC1119452          DOI： 10.1136/bmj.322.7280.183

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  Measles, mumps, rubella vaccine: through a glass, darkly.

Authors:  A J Wakefield; S M Montgomery
Journal:  Adverse Drug React Toxicol Rev       Date:  2000-12

2.  Impact of anti-vaccine movements on pertussis control: the untold story.

Authors:  E J Gangarosa; A M Galazka; C R Wolfe; L M Phillips; R E Gangarosa; E Miller; R T Chen
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

3.  No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study.

Authors:  H Peltola; A Patja; P Leinikki; M Valle; I Davidkin; M Paunio
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

4.  Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals.

Authors:  M Petrovic; R Roberts; M Ramsay
Journal:  BMJ       Date:  2001-01-13

5.  Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.

Authors:  J Stokes; R E Weibel; V M Villarejos; J A Arguedas; E B Buynak; M R Hilleman
Journal:  JAMA       Date:  1971-10-04       Impact factor: 56.272

6.  The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.

Authors:  M Pareek; H M Pattison
Journal:  Br J Gen Pract       Date:  2000-12       Impact factor: 5.386

7.  Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

Authors:  A Patja; I Davidkin; T Kurki; M J Kallio; M Valle; H Peltola
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

8.  Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association.

Authors:  B Taylor; E Miller; C P Farrington; M C Petropoulos; I Favot-Mayaud; J Li; P A Waight
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

9.  Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.

Authors:  A J Wakefield; S H Murch; A Anthony; J Linnell; D M Casson; M Malik; M Berelowitz; A P Dhillon; M A Thomson; P Harvey; A Valentine; S E Davies; J A Walker-Smith
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

10.  A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.

Authors:  P Farrington; S Pugh; A Colville; A Flower; J Nash; P Morgan-Capner; M Rush; E Miller
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321
View more
  5 in total

1.  The discomfort of patient power.

Authors:  Richard Smith
Journal:  BMJ       Date:  2002-03-02

Review 2.  Ethical debate: Vaccination against mumps, measles, and rubella: is there a case for deepening the debate? How safe is MMR vaccine?

Authors:  T Heller
Journal:  BMJ       Date:  2001-10-13

3.  Delivering equitable care: comparing preventive services in Manitoba.

Authors:  Sumit Gupta; Leslie L Roos; Randy Walld; Dawn Traverse; Matthew Dahl
Journal:  Am J Public Health       Date:  2003-12       Impact factor: 9.308

4.  Restoring confidence in vaccines by explaining vaccine safety monitoring: is a targeted approach needed?

Authors:  Rachel E Casiday; Anthony R Cox
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Overview of vaccines and vaccination.

Authors:  Gordon Ada
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.